Gut Microbiota in Human Immunodeficiency Virus-Infected Individuals Linked to Coronary Heart Disease.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
09 01 2019
Historique:
received: 11 05 2018
accepted: 28 08 2018
pubmed: 12 9 2018
medline: 13 11 2019
entrez: 12 9 2018
Statut: ppublish

Résumé

Human immunodeficiency virus (HIV) infection is an independent risk factor for coronary heart disease (CHD) and is associated with perturbation of the gut microbiota. We analyzed gut microbiota in 30 HIV-infected individuals with CHD (CHD+) and 30 without CHD (CHD-) of the HIV-HEART study group. Gut microbiota linked to CHD was associated with lower α-diversity. Despite insignificant differences in β-diversity, co-occurrence networks of bacterial genera clearly diverged between CHD+ and CHD- individuals. Multidimensional scaling separated HIV-infected individuals into 2 microbiome clusters, dominated by the genus Prevotella or Bacteroides. The relative abundance of 49 other genera was significantly different between both clusters. The Prevotella-rich cluster was largely composed of men who have sex with men (MSM) (97%), whereas the Bacteroides-rich cluster comprised both MSM (45%) and heterosexual individuals (55%). MSM of the Bacteroides-rich cluster were characterized by reduced α-diversity, advanced immunological HIV stage, longer antiretroviral therapy with more ART regimens, and longer use of protease inhibitors, compared with Prevotella-rich MSM. Community structures of gut microbiota rather than individual species might facilitate risk assessment of CHD in HIV-infected individuals. Sexual behavior appears to be an important factor affecting gut microbiota β-diversity and should be considered in future studies.

Sections du résumé

Background
Human immunodeficiency virus (HIV) infection is an independent risk factor for coronary heart disease (CHD) and is associated with perturbation of the gut microbiota.
Methods
We analyzed gut microbiota in 30 HIV-infected individuals with CHD (CHD+) and 30 without CHD (CHD-) of the HIV-HEART study group.
Results
Gut microbiota linked to CHD was associated with lower α-diversity. Despite insignificant differences in β-diversity, co-occurrence networks of bacterial genera clearly diverged between CHD+ and CHD- individuals. Multidimensional scaling separated HIV-infected individuals into 2 microbiome clusters, dominated by the genus Prevotella or Bacteroides. The relative abundance of 49 other genera was significantly different between both clusters. The Prevotella-rich cluster was largely composed of men who have sex with men (MSM) (97%), whereas the Bacteroides-rich cluster comprised both MSM (45%) and heterosexual individuals (55%). MSM of the Bacteroides-rich cluster were characterized by reduced α-diversity, advanced immunological HIV stage, longer antiretroviral therapy with more ART regimens, and longer use of protease inhibitors, compared with Prevotella-rich MSM.
Conclusions
Community structures of gut microbiota rather than individual species might facilitate risk assessment of CHD in HIV-infected individuals. Sexual behavior appears to be an important factor affecting gut microbiota β-diversity and should be considered in future studies.

Identifiants

pubmed: 30202890
pii: 5092661
doi: 10.1093/infdis/jiy524
doi:

Substances chimiques

Methylamines 0
trimethyloxamine FLD0K1SJ1A

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

497-508

Auteurs

Jan Kehrmann (J)

Institute of Medical Microbiology, University Hospital Essen.

Jannis Menzel (J)

Institute of Medical Microbiology, University Hospital Essen.

Mohammadkarim Saeedghalati (M)

Centre for Medical Biotechnology, University of Duisburg-Essen, Essen.

Rima Obeid (R)

Department of Clinical Chemistry and Laboratory, Saarland University Hospital, Homburg/Saar.

Christina Schulze (C)

Clinic for Dermatology and Venerology, University of Duisburg-Essen.

Volker Holzendorf (V)

Clinical Trial Centre Leipzig, University of Leipzig.

Farnoush Farahpour (F)

Centre for Medical Biotechnology, University of Duisburg-Essen, Essen.

Nico Reinsch (N)

Department of Internal Medicine I and Cardiology, Division of Electrophysiology, Alfried Krupp von Bohlen and Halbach Hospital, Essen.
Department of Cardiology, Witten/Herdecke University, Witten.

Ludger Klein-Hitpass (L)

Biochip Laboratory, Institute for Cell Biology-Tumor Research.

Handrik Streeck (H)

Institute for HIV Research, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Daniel Hoffmann (D)

Centre for Medical Biotechnology, University of Duisburg-Essen, Essen.

Jan Buer (J)

Institute of Medical Microbiology, University Hospital Essen.

Stefan Esser (S)

Clinic for Dermatology and Venerology, University of Duisburg-Essen.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH